Phase II trial of irinotecan and cisplatin with early concurrent radiotherapy in limited‐disease small‐cell lung cancer
2007; Wiley; Volume: 109; Issue: 9 Linguagem: Inglês
10.1002/cncr.22621
ISSN1097-0142
AutoresJoohyuk Sohn, Yong Wha Moon, Chang Geol Lee, Gwi Eon Kim, Kyung Soo Chung, Joon Chang, Soon Il Kim, Young Sam Kim, Byoung Wook Choi, Hye Jin Choi, Joo‐Hang Kim,
Tópico(s)Neuroendocrine Tumor Research Advances
ResumoA Phase II trial of irinotecan and cisplatin (IP) with early concurrent radiotherapy was performed in limited-disease small-cell lung cancer (LD-SCLC) to evaluate the efficacy and toxicity.For untreated LD-SCLC patients, irinotecan (60 mg/m2, Days 1, 8, and 15) and cisplatin (40 mg/m2, Days 1 and 8) were repeated every 4 weeks for a maximum of 6 cycles. Thoracic radiotherapy of 1.8 Gy/day was begun on Day 1 of the second chemotherapy cycle, up to a total of 45 to 54 Gy. Prophylactic cranial irradiation (30 Gy in 10 fractions) was performed on patients with a complete response (CR).Thirty-three LD-SCLC patients were enrolled. The median age was 60 years and 31 patients had an Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 1. Twelve (36.4%) patients had N3 disease. The response rate was 87.9%, with a CR rate of 45.5%. At a median follow-up period of 27 months the median progression-free survival (PFS) and overall survival (OS) were 14.4 and 26.1 months, respectively, with 2-year PFS and OS rates of 26.8% and 54.9%. The dominating toxicity was neutropenia, with grade 3-5 of 81.8%. The most common grade 3-5 nonhematologic toxicities were diarrhea (21.2%), anorexia (21.2%), and fatigue (21.2%). Grade 3-5 radiation esophagitis and pneumonitis occurred in 18.2% and 9.1% of patients, respectively. There were 2 treatment-related deaths from sepsis and radiation pneumonitis.IP with early concurrent radiotherapy was effective and tolerable in untreated LD-SCLC.
Referência(s)